Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to “Strong Sell” Rating by Zacks Research

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by investment analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Thursday,Zacks.com reports.

A number of other equities analysts have also commented on the company. Stifel Nicolaus raised their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. TD Cowen raised their price target on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Bank of America started coverage on Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price target for the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Finally, Piper Sandler raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $40.00 to $65.00 in a report on Thursday, October 9th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $61.60.

Supernus Pharmaceuticals Stock Down 1.8%

NASDAQ SUPN opened at $48.16 on Thursday. The company has a market capitalization of $2.76 billion, a P/E ratio of -141.64, a P/E/G ratio of 0.52 and a beta of 0.67. Supernus Pharmaceuticals has a 12-month low of $29.16 and a 12-month high of $57.65. The firm has a 50-day moving average price of $48.76 and a two-hundred day moving average price of $46.10.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 EPS for the quarter, missing the consensus estimate of $0.82 by ($0.36). Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The business had revenue of $170.00 million for the quarter, compared to the consensus estimate of $175.82 million. During the same period in the prior year, the business posted $0.69 earnings per share. The firm’s revenue for the quarter was up 9.3% compared to the same quarter last year. Equities analysts expect that Supernus Pharmaceuticals will post 2.38 EPS for the current year.

Insider Transactions at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares in the company, valued at $781,153.36. This represents a 56.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 710 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the transaction, the vice president directly owned 14,508 shares of the company’s stock, valued at approximately $644,735.52. The trade was a 4.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 8.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Rubric Capital Management LP bought a new stake in Supernus Pharmaceuticals during the 2nd quarter worth $21,908,000. Woodline Partners LP raised its position in Supernus Pharmaceuticals by 63.5% in the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after purchasing an additional 490,835 shares during the last quarter. Bank of America Corp DE raised its position in Supernus Pharmaceuticals by 67.1% in the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after purchasing an additional 338,584 shares during the last quarter. UBS Group AG grew its holdings in shares of Supernus Pharmaceuticals by 137.6% during the third quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock worth $25,812,000 after purchasing an additional 312,775 shares during the last quarter. Finally, Sofinnova Investments Inc. grew its holdings in shares of Supernus Pharmaceuticals by 53.5% during the second quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock worth $25,192,000 after purchasing an additional 278,575 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.